Northern Trust Corp Purchases 22,827 Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

Northern Trust Corp grew its position in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) by 35.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 86,957 shares of the company's stock after buying an additional 22,827 shares during the quarter. Northern Trust Corp owned 0.33% of Eton Pharmaceuticals worth $1,158,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of ETON. Tower Research Capital LLC TRC purchased a new stake in shares of Eton Pharmaceuticals during the 4th quarter valued at about $86,000. Raymond James Financial Inc. bought a new stake in Eton Pharmaceuticals during the fourth quarter valued at approximately $147,000. XTX Topco Ltd grew its position in Eton Pharmaceuticals by 29.6% during the fourth quarter. XTX Topco Ltd now owns 14,655 shares of the company's stock valued at $195,000 after buying an additional 3,351 shares during the period. Hillsdale Investment Management Inc. purchased a new stake in Eton Pharmaceuticals during the fourth quarter valued at approximately $226,000. Finally, Envestnet Asset Management Inc. purchased a new stake in Eton Pharmaceuticals during the fourth quarter valued at approximately $236,000. Institutional investors own 27.86% of the company's stock.

Eton Pharmaceuticals Trading Down 0.1%

Eton Pharmaceuticals stock traded down $0.02 during midday trading on Friday, hitting $18.90. The stock had a trading volume of 428,570 shares, compared to its average volume of 204,093. Eton Pharmaceuticals, Inc. has a 52-week low of $3.18 and a 52-week high of $21.48. The company has a market capitalization of $506.86 million, a PE ratio of -85.91 and a beta of 1.22. The firm's fifty day moving average is $15.81 and its two-hundred day moving average is $14.64.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.09 by ($0.02). The firm had revenue of $17.28 million during the quarter, compared to analysts' expectations of $14.33 million. Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%. As a group, equities research analysts predict that Eton Pharmaceuticals, Inc. will post -0.14 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ETON. HC Wainwright reiterated a "buy" rating and set a $35.00 price target (up previously from $33.00) on shares of Eton Pharmaceuticals in a research note on Thursday. Craig Hallum raised their target price on Eton Pharmaceuticals from $26.00 to $28.00 and gave the stock a "buy" rating in a report on Wednesday, May 14th. Finally, B. Riley reissued a "buy" rating and set a $26.00 price target (up previously from $24.00) on shares of Eton Pharmaceuticals in a report on Friday, May 16th.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.